Back to Market Feed

Product Information

KATERZIA 1 MG/ML SUSPENSION is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $4.2005 per ML under NDC 52652500101. Its NADAC has been published 331 times since Apr 22, 2020.

FDA first approved this application on Jul 8, 2019.

KATERZIA 1 MG/ML SUSPENSION

Amlodipine
$4.2005per ML

Strength

1 mg/mL

NDC

52652500101

Classification

Brand

Dosage Form

SUSPENSION

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

AMLODIPINE BENZOATE

Approval Type

New Drug (NDA)

FDA Application

NDA211340

FDA Approved

7/8/2019

On Market Since

8/15/2019

Pharmacological Classes

Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A Inhibitors
Dihydropyridine Calcium Channel Blocker
Dihydropyridines

Price Statistics

The NADAC for KATERZIA 1 MG/ML SUSPENSION has been published 331 times since Apr 22, 2020, and over the history we have for it it has risen 33.1%. The table below summarizes its recorded NADAC range and movement.

Current price$4.2005 per ML
All-time high$4.2151 (Jun 10, 2026)
All-time low$3.1564 (Apr 22, 2020)
52-week high$4.2151
52-week low$4.0635
Median price$3.5311
Average price$3.6243
Largest weekly change+9.0% (Jan 15, 2025)
Weeks tracked331
Tracking sinceApr 22, 2020

Price History

1W

-0.0%

1M

-0.0%

3M

-0.3%

6M

+0.2%

1Y

+3.4%

3Y

+19.0%

5Y

+28.5%

All

+33.1%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Amlodipine market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

TIAZAC ER 180 MG CAPSULE
Brand
00187261330•Bausch Health US LLC
$1.5060
per EA
TIAZAC ER 180 MG CAPSULE
Brand
00187261390•Bausch Health US LLC
$1.5060
per EA
MYRBETRIQ ER 8 MG/ML SUSP
Brand
00469502099•Astellas Pharma US, Inc.
$2.2069
per ML
TIAZAC ER 360 MG CAPSULE
Brand
00187261630•Bausch Health US LLC
$2.7628
per EA
TIAZAC ER 360 MG CAPSULE
Brand
00187261690•Bausch Health US LLC
$2.7628
per EA
KALETRA 80 MG-20 MG/ML SOLN
Brand
00074395646•AbbVie Inc.
$3.1186
per ML
NORLIQVA 1 MG/ML SOLUTION
Brand
46287003515•CMP Pharma, Inc.
$3.2153
per ML
CARDIZEM LA 120 MG TABLET
Brand
00187204530•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 120 MG TABLET
Brand
00187204590•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 180 MG TABLET
Brand
00187204630•Bausch Health US LLC
$3.8314
per EA

Frequently asked questions

What is the NADAC price of KATERZIA 1 MG/ML SUSPENSION?

The current National Average Drug Acquisition Cost (NADAC) for KATERZIA 1 MG/ML SUSPENSION, manufactured by Azurity Pharmaceuticals Inc., is $4.2005 per ML (NDC 52652500101), effective Aug 19, 2026.

How has the price of KATERZIA 1 MG/ML SUSPENSION changed over time?

Over the history we have for it, the NADAC for KATERZIA 1 MG/ML SUSPENSION has risen 33.1%. It has been tracked across 331 weekly CMS publications since Apr 22, 2020.

What are the highest and lowest recorded NADAC prices for KATERZIA 1 MG/ML SUSPENSION?

Since Apr 22, 2020, the NADAC for KATERZIA 1 MG/ML SUSPENSION has ranged from a low of $3.1564 (Apr 22, 2020) to a high of $4.2151 (Jun 10, 2026), with a median of $3.5311 per ML.

Are there cheaper alternatives to KATERZIA 1 MG/ML SUSPENSION?

No other NADAC-published product currently shares the active ingredient and strength of KATERZIA 1 MG/ML SUSPENSION in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures KATERZIA 1 MG/ML SUSPENSION?

KATERZIA 1 MG/ML SUSPENSION (NDC 52652500101) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.